Editorial: Optimizing the first-line treatment for metastatic colorectal cancer

Editorial: Optimizing the first-line treatment for metastatic colorectal cancer

Bibliographic Details
Main Authors:	Davide Ciardiello, Angelica Petrillo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	CRC (colorectal cancer) anti-EGFR panitumumab QOL (quality of life) liver metastasis biomarkers
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1366383/full

Similar Items

Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
by: Qian Wu, et al.
Published: (2022-08-01)

Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
by: Yi‐Hsin Liang, et al.
Published: (2023-07-01)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
by: Thaler Josef, et al.
Published: (2012-09-01)

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study
by: M. Yu. Fedyanin, et al.
Published: (2019-06-01)

First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
by: Vogel Arndt, et al.
Published: (2018-05-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
by: J. Sgouros, et al.
Published: (2025-03-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
by: Changjing Cai, et al.
Published: (2022-09-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials
by: Yang Wang, et al.
Published: (2023-10-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Pathologic complete response in metastatic right-sided colon cancer treated with panitumumab and FOLFOX4 chemotherapy regimen
by: Džunić Miljana, et al.
Published: (2022-01-01)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
by: Buchler T, et al.
Published: (2018-12-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
by: Munenobu Kashiwa, et al.
Published: (2021-10-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
by: Ho Wai Derrick Siu, et al.
Published: (2021-08-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Differences in tissue-associated bacteria between metastatic and non-metastatic colorectal cancer
by: Peng Zhou, et al.
Published: (2023-06-01)

Second-line panitumumab as a triweekly dose for patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer: a single-institution experience
by: Mohamed A. Daoud, et al.
Published: (2016-03-01)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
by: Giulia Martini, et al.
Published: (2023-02-01)

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study
by: Gudrun Piringer, et al.
Published: (2023-08-01)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
by: Alessandro Parisi, et al.
Published: (2021-10-01)

Multimodal Machine Learning for Predicting Post-Surgery Quality of Life in Colorectal Cancer Patients
by: Maryem Rhanoui, et al.
Published: (2024-11-01)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
by: Brigida Anna Maiorano, et al.
Published: (2022-10-01)

Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency
by: R. T. Ayupov, et al.
Published: (2021-12-01)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
by: Hua Ye, et al.
Published: (2020-07-01)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
by: Tetsuji Terazawa, et al.
Published: (2019-06-01)

The Relationship of Smoking and Lymph Node Metastasis with Survival in Colorectal Cancers
by: Sevda Yeşim ÖZDEMİR, et al.
Published: (2022-08-01)

Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report
by: Atsushi Kawasaki, et al.
Published: (2013-05-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
by: Sadaf Aghevlian, et al.
Published: (2020-11-01)

Exosomes promote pre-metastatic niche formation in colorectal cancer
by: Guifei Si, et al.
Published: (2024-03-01)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
by: G. Sommerhäuser, et al.
Published: (2022-07-01)

Tumor circulating biomarkers in colorectal cancer
by: Raana Bagheri, et al.
Published: (2024-01-01)